BioverSys AG bags $15m CARB-X funding
CARB-X is funding Swiss pharma company BioVersys with $15.2m to develop a new class of antibiotics to treat infections caused by multidrug-resistant pathogens.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Lonza expands EU production capacity for Moderna vaccine
/in News/by Thomas GabrielczykLonza will expand its production capacity of Modernas mRNA vaccine mRNA1273 at its manufacturing site in Geelen, the Netherlands.
EU approves Biontech/Pfizer vaccine for adolescents
/in News/by Thomas GabrielczykThe European Medicines Agency (EMA) has given the green light for vaccination of adolescents with Biontech’s COVID-19 vaccine Comirnaty (BNT162b2).
Senti Bio and Bluerock ink Regmed collaboration
/in News/by Thomas GabrielczykSenti Biosciences and Bayer subsidiary BlueRock Therapeutics form strategic partnership to combine iPSC and gene circuit-engineered cell therapy platforms.
Pieris in $1.4bn deal with Roche
/in News/by Thomas GabrielczykGerman-US Anticalin specialist Pieris Pharmaceuticals has bagged $20m upfront for a strategic R&D and license agreement with Genentech, the US branch of Swiss Roche AG.
Associations call for acceleration of ATMP trials in Europe
/in News/by Thomas GabrielczykLife science associations are calling for ATMPs to be exempted from the strict EU GMO rules, as their different legal interpretations in EU member states are delaying applications for multicentre […]
COVID-19 med APN01 selected to be tested in ACTIV study
/in News/by Thomas GabrielczykAPEIRON Biologics recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds.
Hummingbird Bioscience raises $125m in Series C financing
/in News/by Thomas GabrielczykDanish Novo Holdings A/S has led an oversubscribed US$125m Series C into the cancer antibody specialist Hummingbird Bioscience.
BD installs production hub in Zaraogza
/in News/by Thomas GabrielczykBD will build a 165m manufacturing facility in Zaragoza, Spain to support the growth of its pre-filled drug delivery business.
COVID-19 therapeutics: Germany launches 300m funding
/in News/by Thomas GabrielczykGerman government has launched a 300m programme designed to bring clinically tested COVID-19 treatments to the patient’s bedside.